---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-008230"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T14:50:31.120385+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sagimet Biosciences prices public offering of 9M shares at $12.50/share, raising $112.5M gross

## Summary
- Priced 9,000,000 shares of Series A common stock at $12.50/share; gross proceeds ~$112.5M before expenses.
- Underwriters granted 30-day option to purchase up to 1,350,000 additional shares at the offering price.
- Net proceeds to fund denifanstat Phase 3 program in NASH, TVB-3567 IND for acne, and general corporate.
- Offering closed January 30, 2024; Goldman Sachs, TD Cowen, and Leerink acted as joint book-running managers.
- All shares sold by Sagimet; no selling stockholders in the offering.

## SEC filing metadata
- accession: 0001104659-24-008230
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924008230/0001104659-24-008230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924008230/tm244525d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-008230
- JSON: https://secwatch.observer/filing/0001104659-24-008230.json
- Plain text: https://secwatch.observer/filing/0001104659-24-008230.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.